The AAPS Journal

, Volume 8, Issue 3, pp E532–E551

Immunotoxins for targeted cancer therapy


DOI: 10.1208/aapsj080363

Cite this article as:
Kreitman, R.J. AAPS J (2006) 8: E532. doi:10.1208/aapsj080363


Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting protein synthesis. For the immunotoxin to work, it must bind to and be internalized by the target cells, and the enzymatic fragment of the toxin must translocate to the cytosol. Once in the cytosol, 1 molecule is capable of killing a cell, making immunotoxins some of the most potent killing agents. Various plant and bacterial toxins have been genetically fused or chemically conjugated to ligands that bind to cancer cells. Among the most active clinically are those that bind to hematologic tumors. At present, only 1 agent, which contains human interleukin-2 and truncated diphtheria toxin, is approved for use in cutaneous T-cell lymphoma. Another, containing an anti-CD22 Fv and truncatedPseudomonas exotoxin, has induced complete remissions in a high proportion of cases of hairy-cell leukemia. Refinement of existing immunotoxins and development of new immunotoxins are underway to improve the treatment of cancer.


Monoclonal antibody CD22 CD25 interleukin Pseudomonas diphtheria 

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  1. 1.Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer InstituteNational Institutes of HealthBethesda

Personalised recommendations